Quest Diagnostics (NYSE: DGX), the nation’s leading provider of diagnostic information services, and Haystack Oncology, an early-stage oncology company focused on minimal residual disease (MRD) testing to aid in the early, accurate detection of residual or recurring cancer and better inform therapy decisions, has announced a definitive agreement for Quest to acquire Haystack in an all-cash equity transaction. MRD testing is a fast-growing category of liquid biopsy tests that identify circulating tumor DNA (ctDNA) in the bloodstream of patients following surgery and treatment for cancer. Under the terms of the agreement, Quest will pay $300 million in cash at closing, net of cash acquired, and up to an additional $150 million on achieving future performance milestones.
Read the full article: Quest Diagnostics to Acquire Haystack Oncology //
Source: https://www.prnewswire.com/news-releases/quest-diagnostics-to-acquire-haystack-oncology-adding-sensitive-liquid-biopsy-technology-for-improving-personalized-cancer-care-to-oncology-portfolio-301808987.html